27.87
+0.56
+(2.05%)
At close: April 16 at 4:00:01 PM EDT
27.87
0.00
(0.00%)
After hours: April 16 at 4:05:05 PM EDT
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
310,202
310,202
249,428
174,361
36,484
Cost of Revenue
2,731
2,731
1,037
1,089
--
Gross Profit
307,471
307,471
248,391
173,272
36,484
Operating Expense
377,932
377,932
308,040
224,980
211,071
Operating Income
-70,461
-70,461
-59,649
-51,708
-174,587
Net Non Operating Interest Income Expense
6,774
6,774
12,832
-1,653
-5,508
Other Income Expense
10,750
10,750
-14,073
12,478
216
Pretax Income
-52,937
-52,937
-60,890
-40,883
-179,879
Tax Provision
-1,850
-1,850
-5,603
11,660
150
Net Income Common Stockholders
-51,087
-51,087
-55,287
-52,543
-180,029
Diluted NI Available to Com Stockholders
-51,087
-51,087
-55,287
-52,543
-180,029
Basic EPS
-1.02
-1.02
-1.13
-1.09
-4.05
Diluted EPS
-1.02
-1.02
-1.13
-1.09
-4.05
Basic Average Shares
49,991.06
49,991.06
48,888.98
45,804.44
43,862.85
Diluted Average Shares
49,991.06
49,991.06
48,888.98
45,804.44
43,862.85
Total Operating Income as Reported
-70,461
-70,461
-59,649
-51,708
-174,587
Total Expenses
380,663
380,663
309,077
226,069
211,071
Net Income from Continuing & Discontinued Operation
-51,087
-51,087
-55,287
-52,543
-180,029
Normalized Income
-47,763.13
-47,763.13
-43,323.19
-62,665.26
-180,317.71
Interest Income
25,618
25,618
17,986
3,756
65
Interest Expense
18,844
18,844
5,154
5,409
5,573
Net Interest Income
6,774
6,774
12,832
-1,653
-5,508
EBIT
-34,093
-34,093
-55,736
-35,474
-174,306
EBITDA
-29,889
-29,889
-51,646
-30,139
-166,715
Reconciled Cost of Revenue
2,731
2,731
1,037
1,089
--
Reconciled Depreciation
4,204
4,204
4,090
5,335
7,591
Net Income from Continuing Operation Net Minority Interest
-51,087
-51,087
-55,287
-52,543
-180,029
Total Unusual Items Excluding Goodwill
-3,448
-3,448
-13,176
14,157
289
Total Unusual Items
-3,448
-3,448
-13,176
14,157
289
Normalized EBITDA
-26,441
-26,441
-38,470
-44,296
-167,004
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-124.13
-124.13
-1,212.19
4,034.75
0.29
12/31/2021 - 2/5/2021
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
IDYA IDEAYA Biosciences, Inc.
16.18
-4.71%
CGEM Cullinan Therapeutics, Inc.
7.61
-2.44%
RVMD Revolution Medicines, Inc.
36.20
-0.33%
REPL Replimune Group, Inc.
7.63
-1.04%
SNDX Syndax Pharmaceuticals, Inc.
11.05
-2.47%
NRIX Nurix Therapeutics, Inc.
9.80
-0.20%
SYRE Spyre Therapeutics, Inc.
12.42
-2.28%
MLTX MoonLake Immunotherapeutics
36.97
+0.54%
BPMC Blueprint Medicines Corporation
82.11
+0.81%
JANX Janux Therapeutics, Inc.
28.69
-1.27%